Jubilant Life Sciences announced on Friday that it has received approval from the US Food and Drugs Administration (FDA) to market a generic diuretic medicine.
The company has received abbreviated new drug application approval to market Spironolactone tablets (25 mg, 50 mg and 100 mg). These tablets are the generic version of GD Searle's Aldactone. Spironolactone is used to treat fluid retention caused by conditions such as congestive heart failure and cirrhosis of the liver.
Jubilant said in a press release that it will launch the drug in the first quarter of the fiscal year 2015-16. The market size of this diuretic is estimated to be $87 million per year.